Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MORNASDAQ:MRUSNYSE:OGNNASDAQ:RTRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMRUSMerus$52.74-0.7%$48.03$33.19▼$62.98$3.68B1.04753,292 shs748,995 shsOGNOrganon & Co.$9.82+0.7%$9.86$8.01▼$23.10$2.53B0.593.45 million shs3.28 million shsRTRXTravere Therapeutics$14.49+1.3%$26.56$8.98▼$24.96$739.74M0.67412,277 shs885,034 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%+4.18%MRUSMerus-0.68%-1.05%-4.35%+12.26%-3.83%OGNOrganon & Co.+0.56%-3.75%+13.00%-33.38%-52.88%RTRXTravere Therapeutics0.00%-1.31%-9.66%-32.79%+95.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus3.1593 of 5 stars4.63.00.00.02.11.70.0OGNOrganon & Co.4.6908 of 5 stars3.32.01.73.71.73.32.5RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMORMorphoSys 0.00N/AN/AN/AMRUSMerus 3.14Buy$84.6460.48% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0083.30% UpsideRTRXTravere Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RTRX, MRUS, OGN, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.004/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MRUSMerus$36.13M101.03N/AN/A$9.46 per share5.58OGNOrganon & Co.$6.40B0.40$4.96 per share1.98$1.83 per share5.37RTRXTravere Therapeutics$175.34M4.22N/AN/A$5.15 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)OGNOrganon & Co.$864M$2.883.412.631.0211.92%227.43%7.34%8/5/2025 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ALatest RTRX, MRUS, OGN, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMORMorphoSysN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.81%N/A2.78%N/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ALatest RTRX, MRUS, OGN, and MOR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMORMorphoSys4.981.381.38MRUSMerusN/A5.865.86OGNOrganon & Co.16.491.671.15RTRXTravere Therapeutics0.667.237.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMORMorphoSys18.38%MRUSMerus96.14%OGNOrganon & Co.77.43%RTRXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipMORMorphoSys0.05%MRUSMerus4.57%OGNOrganon & Co.1.40%RTRXTravere Therapeutics4.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMRUSMerus3769.21 million66.05 millionOptionableOGNOrganon & Co.4,000259.96 million256.32 millionNot OptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableRTRX, MRUS, OGN, and MOR HeadlinesRecent News About These CompaniesTravere taps Grammy-winning producer to create anthem for kidney disease patientsJune 11, 2025 | fiercepharma.comTravere Therapeutics’ sNDA for FILSPARI accepted by FDAMay 17, 2025 | uk.investing.comIBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's WhyMay 16, 2025 | msn.comTravere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off WorriesMay 16, 2025 | msn.comTravere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS TreatmentMay 6, 2025 | msn.comTravere Therapeutics anticipates FILSPARI approval for FSGS by September 2025May 2, 2025 | msn.comTravere Therapeutics price target lowered to $30 from $32 at ScotiabankApril 11, 2025 | markets.businessinsider.comTravere Therapeutics price target raised to $47 from $45 at CanaccordApril 11, 2025 | markets.businessinsider.comTravere Therapeutics price target lowered to $27 from $31 at BofAApril 4, 2025 | markets.businessinsider.comNovartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug ApprovalApril 3, 2025 | msn.comTravere Therapeutics price target raised to $31 from $29 at BofAApril 2, 2025 | markets.businessinsider.comTravere weaker after Filspari fails confirmatory trialMarch 25, 2025 | pharmaphorum.comTravere Therapeutics price target raised to $44 from $42 at JPMorganFebruary 26, 2025 | markets.businessinsider.comTravere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling RecentlyFebruary 14, 2025 | msn.comTravere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares RallyFebruary 11, 2025 | marketwatch.comTravere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease DrugFebruary 11, 2025 | msn.comTravere therapeutics CFO sells $104,463 in stockFebruary 5, 2025 | msn.comTravere therapeutics executive sells shares worth $106,081February 5, 2025 | msn.comTravere therapeutics chief commercial officer sells $30,002 in stockJanuary 25, 2025 | msn.comTravere Therapeutics Inc (TVTX) Reported a -137.48% Operating Margin Last Year—What’s the Real Story?January 23, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching2 Red-Hot Stocks With High RSIs and More Upside to ComeBy Sam Quirke | May 27, 2025View 2 Red-Hot Stocks With High RSIs and More Upside to ComeRTRX, MRUS, OGN, and MOR Company DescriptionsMorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 06/20/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Merus NASDAQ:MRUS$52.74 -0.36 (-0.68%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$52.74 0.00 (0.00%) As of 06:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Organon & Co. NYSE:OGN$9.82 +0.07 (+0.72%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$9.83 +0.01 (+0.11%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Travere Therapeutics NASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
